Navigation Links
MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
Date:6/10/2009

WARREN, N.J., June 10 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today that the new drug application (NDA) for ondansetron orally dissolving film strip (ODFS) has been accepted for review by the U.S. Food and Drug Administration (FDA). Ondansetron ODFS was developed using MonoSol Rx's proprietary PharmFilm(R) technology to deliver the anti-emetic therapy ondansetron in a thin film strip that rapidly dissolves on the tongue.

MonoSol Rx and its partner Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), are seeking FDA approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery. The NDA is supported by positive data from successfully completed pivotal bioequivalence studies against ondansetron ODT (orally disintegrating tablets), both with and without water. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, the FDA is expected to respond to the NDA by the first quarter of 2010.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "The FDA's acceptance of the NDA for our ondansetron orally dissolving film strip further validates the acceptance of thin film as a new prescription dosage form. With our licensing partner Strativa we are one step closer to providing a promising new formulation of an anti-emetic therapy that leverages our PharmFilm(R) drug delivery technology. By delivering the drug orally through a rapidly dissolving film strip that requires no water, ondansetron ODFS has advantages over tablets or liquid medications, which can exacerbate nausea in these patients."

The anti-emetic marke
'/>"/>

SOURCE MonoSol Rx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
2. MonoSol Rx Granted U.S. Article of Manufacture Patent
3. MonoSol Rx Enters Agreement with Hikma Pharmaceuticals PLC for Thin Film Pharmaceutical Products in the Middle East
4. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
5. MonoSol Rx to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
7. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
8. MonoSol Rx Names Vincent Viviani Senior Vice President, Manufacturing and Operations
9. MonoSol Rx Granted US Patent for Thin Film Manufacturing Process
10. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
11. Forterus Inc. Announces Special Board Meeting; Nominates Jeff Walton, Former Bear Stearns President, to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... New York (PRWEB) May 20, 2013 National ... Firm P.A. and Thrash Law Firm P.A., both based in ... final approval of the proposed $7.25 billion settlement of a ... transaction fees. The objection was filed Wednesday, May 15, 2013, ... New York. The related lawsuit against Visa and MasterCard (Case ...
(Date:5/20/2013)... is proud to announce the publication of the much-anticipated ... A. Weinberg. , The First Edition has been ... the most important advances in the fast-growing field of ... all of its hallmark features admired by students, instructors, ... of Cancer is a textbook for students studying the ...
(Date:5/20/2013)... 2013 For more than forty years, ... battle against drug and alcohol abuse around the world. ... first guide to help Italian speakers reverse growing trends ... European Monitoring Centre for Drugs and Drug Addiction show ... cannabis in the last year. As a glimpse of ...
(Date:5/20/2013)... -- A child whose mother lived near heavy traffic ... a respiratory infection before the age of 3, a ... nearly 1,300 pairs of mothers and infants from eastern ... their first trimester of pregnancy at some point between ... mothers lived within 100 meters (about 110 yards) from ...
(Date:5/20/2013)... fossa subdural hematoma (PFSDH) is a serious and rare ... with appropriate treatment, there,s an excellent chance of good ... a study in the May issue of ... of Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , The results support ...
Breaking Medicine News(10 mins):Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 2Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 3Health News:'The Biology of Cancer' by Robert A. Weinberg 2Health News:First Narconon Cannabis Abuse Prevention Guide Takes Aim at Drug Abuse Statistics for Italian Youth 2Health News:Living Near Major Roadways in Pregnancy Tied to Respiratory Woes in Children 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3
... 11 private healthcare providers into the public NHS system thereby ... sector. //Mr Blair and the health secretary, Patricia Hewitt, welcomed ... to mark the launch of NHS Partners Network. ... towards 'future success' of the NHS. "Wherever people are treated ...
... are at a lesser risk of Parkinson’s, according to ... and Psychiatry. // ,The research team, as ... patients and 106 healthy people, belonging to the same ... sought to throw light on their personality traits and ...
... flu pandemic could claim as much as 140 million ... ,The authors of the report, internationally renowned ... academic Alexandra Sidorenko, estimate that even a mild pandemic ... economy $330 billion in lost production. ,The ...
... in Australia claims to have discovered a novel way ... attention deficit hyperactivity disorder (ADHD). //This novel method, space-age ... space. But it can also be used by the ... , ,Attention deficit hyperactivity disorder (ADHD) is a ...
... firm LG Electronics has said that it will start to ... filter made from using an enzyme contained in the "the ... against the dreaded bird flu virus. ,"We developed ... flu," LG spokeswoman Park Se-won said. The filter was fabricated ...
... are pushing Wal-Mart against a Wall, to cough up more on ... the unions are doing this for the cause of the workers, ... meets the eye. The scene is on the brink of a ... ,The scene at Washington is hotting up with the ...
Cached Medicine News:
(Date:5/20/2013)... WASHINGTON , May 20, 2013  Medicare ... networks are overwhelmingly satisfied, citing lower costs, convenient ... a new survey from Hart Research Associates released ... More than 40% of Part D seniors (9.5 ... networks. "Seniors like the lower costs, ...
(Date:5/19/2013)... 2013  Whole-cell pertussis vaccines were more effective at ... large recent outbreak, according to a new Kaiser Permanente ... also called DTwP, were available from the 1940s to ... led to the development of acellular pertussis vaccines, which ... the United States had switched from ...
(Date:5/17/2013)... -- The power of plants to cure and rejuvenate, ... depends on the plant kingdom, is the subject of ... Medicine: Healing Plants Around the World, Featuring ... 18 through September 8, 2013. (Photo:  ... attractions include a re-creation of the Western world,s oldest ...
Breaking Medicine Technology:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2
... (OTC Bulletin Board: AEMD ), the pioneer ... and cancer, announced today that it has engaged Fabiani ... partnerships that advance biodefense, cancer, and chronic infectious disease ... the first medical device to selectively target the removal ...
... LAIYANG, China, Sept. 30 /PRNewswire-Asia-FirstCall/ -- ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Medicine Technology:Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 2Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 3Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 4Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 5Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 2Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 3Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 4Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 5Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 6Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 7Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 8Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 9Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 10Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 11Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 12Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 13Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 14Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 15Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 16Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 17Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results 18
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... source is a superior choice for machine ... headlamps, and dental curing. This is a ... weight, compact and cost competitve with lower ... source utilizes the latest in Cermax technology, ...
... Test System* is a multiplexed, fluorescent, ... multiple assays from a single sample ... a simple and streamlined alternative to ... clinical sensitivity and comparable clinical specificity ...
... 350 Chemistry System offers easy operation, maintenance, and ... STAT, or back-up to the powerful VITROS 5,1 ... the job done right the first time. Its ... are efficient, dependable, and easy-to-use. The VITROS 350 ...
Medicine Products: